HDM-2017

N/A

Report date: 2026/05/13 15:11:41

Base Information

Drug NameHDM-2017
Drug Alias Nameantibody-drug conjugate (ADC) composed of the humanized monoclonal antibody against CDH17 conjugated to exatecan (a topoisomerase I inhibitor)HDM2017HDM-2017
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-Cadherin-17
TargetsCadherin-17
Therapy Area/IndicationsSolid tumoursColorectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHangzhou Zhongmei Huadong Pharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesHuadong Medicine Co LtdHangzhou Zhongmei Huadong Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursColorectal Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A